Acute toxoplasmosis infection in a patient with ankylosing spondylitis treated with adalimumab: a case report

Toxoplasmosi acuta in un paziente con spondilitis anchilosante trattato con adalimumab: caso clinico

V.F. Azevedo¹, C.F. Pietrovski², M. de Almeida Santos Jr²
¹Hospital de Clínicas, Federal University of Paraná, Brazil;
²Federal University of Paraná, Brazil

The introduction of anti-TNF agents such as infliximab, etanercept and adalimumab was a great step towards control of the disease (3). Despite the good results, anti-TNF alpha therapy has a number of contraindications and side effects, especially when used in combination with classical immunosuppressive agents or corticosteroids. Areas of concern include opportunistic infections, malignancies, and miscellaneous complications, such as injection/infusion reactions and autoimmunity, and contraindications, such as heart failure and acute infectious diseases. Other paradoxical new adverse effects are recognized, i.e. exacerbation or development of new onset psoriasis. Although toxoplasmosis is one of the opportunistic infections, re-activation of latent tuberculosis remains the most important safety issue of anti-TNF therapies (3).

CASE REPORT

A 36-year-old white man with a 12-year history of HLA B27 positive ankylosing spondylitis (AS) with no history of uveitis or gastrointestinal symptoms was treated in our spondylarthropathies clinic because of inflammatory low back pain and peripheral involvement. He had been treated with
NSAIDs, methotrexate and sulphasalazine since 1998, with little improvement in axial and peripheral complaints. In November 2006, treatment with adalimumab 40mg every other week was started. BASDAI was 7.2, erythrocyte sedimentation rate (ESR) 7 mm/h and CRP 2.2 mg/dl. The patient denied previous history or known exposure to tuberculosis, purified protein derivative (PPD) was negative and chest radiograph was normal. In October 2008, 23 months after the beginning of the treatment, he developed cervical and axillary lymphadenomegaly, malaise and headache. There was no low back pain, joint complaints or fever. BASDAI was 3.2. Adalimumab was discontinued and laboratory tests performed: hemoglobin was 14.3 g/dl, white blood cells 10,900 per microliter, ESR 2 mm/h. Liver function, renal function, and urinalysis were normal. Tests for HIV and Epstein-Barr virus (EBV) were negative. Serology for cytomegalovirus (CMV) was positive for IgG fraction. Serology for Toxoplasma gondii (TG) disclosed a positive IgM titer and a negative IgG titer. Chest radiographs, head CT scan, and ophthalmologic examination were all normal. Based on this investigation, a diagnosis of acute toxoplasmosis was suggested and treatment with sulfamethoxazole/trimethoprim and spiramycin, recommended by the infectologist, was started. One week later lymphadenomegaly improved and, after two months, there was complete resolution of the symptoms. Serology for Toxoplasma gondii disclosed negative IgM titer and a slightly positive IgG titer. We reintroduced adalimumab subcutaneously every other two weeks three months after the complete resolution of the symptoms. Six months after the beginning of adalimumab therapy, the patient was well and without severe AS activity or signals/symptoms of toxoplasmosis.

**DISCUSSION**

TG is an obligate intracellular parasite that infects up to a third of the world’s population. Infection is mainly acquired by ingestion of food or water that is contaminated with oocysts shed by cats or by eating undercooked or raw meat containing tissue cysts. Primary infection is usually subclinical, but in some patients cervical lymphadenopathy, ocular disease, encephalitis, myocarditis, and pneumoni-tis can be present. By contrast with the favourable course of toxoplasmosis in almost all immunocompetent individuals, the disease can be life-threatening in the immunocompromised ones. Toxoplasmic chorioretinitis, a common presentation in these individuals, may be seen in the setting of congenital or postnatally acquired disease as a result of acute infection or reactivation (4). Another severe presentation is the central nervous system involvement, classically described in the setting of AIDS (5) and also in the presence of corticosteroids and anti-TNF-alpha therapy (6, 7).

Adalimumab was the first fully human monoclonal antibody targeted against TNF-alpha. As other anti-TNF-alpha agents (etanercept and infliximab), it is licensed for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis (8). TNF inhibition has demonstrated effectiveness in the treatment of AS symptoms and all currently available anti-TNF agents appear to have similar efficacy (9).

More than 300,000 patients worldwide have been treated with adalimumab, which is commercially available in the US and 62 other countries (10), and so far, seems to be safe (11). Anti-TNF-alpha agents can cause infections, malignancies, injection site reactions and others (11-14). Tuberculosis is the most frequent opportunistic infection which has been reported with anti-TNF-alpha therapy (8, 11).

We found a small number of reported cases of toxoplasmosis in patients using anti-TNF therapy: two cases of chorioretinitis (15) and two cases of cerebral toxoplasmosis (6, 7). Based on those cases, Lassoued et al raised the question of a link between toxoplasmosis infection and TNF-alpha antagonists therapy (15).

We did not find any description of acute toxoplasmosis in patients using adalimumab. TNF-alpha plays an important role not only in inflammatory process, but also in the normal response against infections, and as a consequence, blocking this cytokine may increase risk of infectious complications (8). It is known that TNF-alpha has an important role specifically in protection against TG infections playing a synergical role with IFN-gamma (16).

A study conducted by Chang et al revealed that mice treated for 8 days with recombinant murine TNF during infection with a virulent strain of TG were protected against the infection (16). In 1992, Johnson demonstrated that mice infected with a nonvirulent strain of TG developed infection and higher mortality when TNF-neutralizing antibo-
ies were administrated. Although these evidences confirm that TNF is an important mediator of resistance to TG (17), there are few reported cases of toxoplasmosis or other opportunistic infections in patients treated with anti-TNF-alpha therapy and specifically with adalimumab (6, 7, 11, 15).

TG infection has a wide range of manifestations, and its diagnosis can be difficult. General symptoms like malaise, low-grade fever and visual complaints should prompt the investigation towards TG epidemiological and serological parameters. In this setting, an acute form of the disease or its reactivation could be present.

In addition, we suggest that adalimumab can be safely reintroduced after the complete resolution of an acute TG infection.

**REFERENCES**